Why Goldman Sachs just upgraded Pro Medicus shares

Goldman Sachs has upgraded Pro Medicus' shares…

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price will be on watch on Friday.

This follows the release of a positive broker note out of Goldman Sachs this morning.

What is Goldman Sachs saying about Pro Medicus' shares?

According to the note, the broker has taken its sell rating off the health imaging technology company's shares.

Goldman has upgraded Pro Medicus to a neutral rating with an improved price target of $42.60.

And while this is still lower than the current Pro Medicus share price of $45.19, the broker spoke very positively about the company's outlook and artificial intelligence (AI) opportunity.

What did the broker say?

Goldman Sachs highlights that over the last decade there has been a lot written about the various benefits and applications of AI in radiology. At long last, the broker believes that the technology is finally approaching a tipping point in adoption.

This could be good news for Pro Medicus, as Goldman Sachs believes it is the company that could benefit most from this technology. And while it acknowledges that it is still early days, the broker sees a big opportunity for the company.

Goldman explained:

Although still early days, we believe PME is better positioned than most to commercialise AI, as integration with its established Visage 7 Viewer provides a strong differentiation to the competition. However, competition is likely to be intense, with multiple players vying for platform share, and hence any sustained success is very far from assured.

Whilst revenue contribution is still subject to various uncertainties, PME is now generating revenue from its breast density AI algorithm, and hence we feel it is now necessary to at least attempt to recognise what could be a meaningful growth driver through the mid/long-term. Based on our current assumptions, AI could be +3-9% accretive to our revenue forecasts in FY24-26E.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »